For Investors
Updates
Our Business
Few things are as important to us as living longer, healthier lives—both mentally and physically. By reimagining and democratizing the clinical research process, RegenMed empowers every physician and their patients to make a meaningful impact, not only on their own health but on the lives of millions of others.
We generate clinical, scientific and financial value from real-world healthcare datasets. Our proprietary and regulatorily-compliant datasets cover a wide range of pathologies, treatment protocols and outcomes measures. Our clients include providers, product manufacturers and other healthcare constituencies around the world.
Our technical platforms are patented. Our processes are integrated, efficient and low-cost. They impose minimum clinical burden on the primary source of real-world evidence – busy physicians and their patients. They also provide multiple incentives to those physicians to create unbiased and clinically impactful datasets.
Read more about our History and Principles
Our Opportunities
Clinical research is largely biased, unaffordable, and clinically irrelevant. Meanwhile, real-world evidence is highly valued by payers, regulators, providers, manufacturers, and patients.
By offering a low-cost yet technically robust software-as-a service solution – with a strong focus on everyday busy physicians – we are in a strong position to fundamentally disrupt the largest markets in healthcare. These include the $500 billion clinical research market and the almost $1 trillion value-based care market.
Our validated and copyrightable “Circles” datasets are also ideal for training AI healthcare models, which depend on an error rate of close to zero.
Our Traction
Our recurring revenue growth the past two six month periods ending June 30, 2024 is 120% and 309%.
What Our Clients Say
Our client list is diverse, growing, international, and loyal. *
* These testimonials may not be representative of the experience of other customers and is no guarantee of future performance or success.
Read more info on the clients’ use cases in the Latest
Our Leadership
Our leadership comprises seasoned SaaS executives, as well internationally recognized medical and scientific thought leaders from some of the most prestigious teaching hospitals in the world, including Atrium Health, Cedars Sinai, Feinstein Institutes For Medical Research, Northwell, and UPMC.
Dr. William J. Futrell
Co-Founder & Chairman
Michael Tierney
Co-Founder and Chief Executive Officer
Nicolas Tierney
Chief Operating Officer
Bert R. Mandelbaum, M.D.
Co-Chair of Medical Affairs, Cedars-Sinai Kerlan-Jobe Institute
Kenneth R. Zaslav, M.D.
Director, Center for Regenerative Orthopedic Med
Claude T. Moorman, III, M.D.
Director, Sports Medicine at Duke University
Learn more about our Leadership
Our Plans
We are offering shares to third parties for the first time. Having already established a strong product market fit, we will use proceeds to strengthen sales, geographic reach, IP development, and dataset licensing opportunities.
or
Disclaimers
This website may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. when used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. the company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.
Our Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.